Drugs Made In America Acquisition (DMAAU) Return on Equity (2025)

Drugs Made In America Acquisition (DMAAU) reported Return on Equity of 0.01% for Q4 2025, down 2.92% quarter-over-quarter from 0.01% in Q3 2025.

Drugs Made In America Acquisition (DMAAU) Return on Equity (2025) Analysis & Trends

Drugs Made In America Acquisition has reported Return on Equity for 1 years, with the latest figure at 0.01% in Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity changed N/A year-over-year to 0.01%; the trailing twelve-month figure through Dec 2025 stood at 0.01% (changed N/A YoY), and the FY2025 full-year result was 0.02%, changed N/A from the prior year.
  • Return on Equity for Q4 2025 stood at 0.01%, down from 0.01% in the prior quarter.
  • The five-year high for Return on Equity was 0.01% in Q3 2025, with the low at 0.01% in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - -0.01%
2 Berto Acquisition 312.46 Mn 312.46 Mn - -0.01%
3 Centurion Acquisition 311.65 Mn 311.65 Mn - -0.01%
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - -0.01%
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - -0.01%
6 WEN Acquisition 309.15 Mn 309.15 Mn - -0.01%
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - -0.01%
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - 0.00%
9 BTC Development 262.16 Mn 262.16 Mn - 0.00%
10 Drugs Made In America Acquisition - - - -0.01%

Historic Data

Download Data
DateValue
Dec 31, 2025 -0.01%
Sep 30, 2025 -0.01%